Tibulizumab

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameTibulizumab
Drug Alias NameLY-3090106LY3090106ZB-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin 17A modulatorsB-cell-activating factor/B lymphocyte stimulator modulators
TargetsB-cell-activating factor/B lymphocyte stimulatorInterleukin 17A
Therapy Area/IndicationsScleroderma, SystemicSjogren-Larsson SyndromeSjogren's Syndrome +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesZura Bio IncZura Bio Ltd
Inactive CompaniesStanford UniversityEli Lilly And Company
Active IndicationsScleroderma, SystemicSjogren's SyndromeArthritis, Rheumatoid +[4] 
Inactive IndicationsSjogren-Larsson Syndrome

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG